重慶市華雅干細(xì)胞技術(shù)有限公司 ，  ：

華雅集團(tuán)旗下授權(quán)代理TTAKARA Cellartis干細(xì)胞產(chǎn)品

DEF-CS是單個(gè)干細(xì)胞基因操作的理想選擇，和目前市場(chǎng)上的相關(guān)產(chǎn)品不同的是，DEF-CS在設(shè)計(jì)上就是支持單細(xì)胞生長(zhǎng)的。

DEF-CS 500誘導(dǎo)多能干細(xì)胞無血清培養(yǎng)基

英文名稱：Cellartis® DEF-CS™ 500 Culture System

中文名稱：Cellartis® DEF-CS™ 500人iPS細(xì)胞無血清培養(yǎng)系統(tǒng)

特點(diǎn)：成分確定 無血清 無飼養(yǎng)層 *培養(yǎng)基

用途：iPS細(xì)胞大規(guī)模培養(yǎng)，單細(xì)胞培養(yǎng)，轉(zhuǎn)染和Scaffold接種。

保存：基礎(chǔ)培養(yǎng)基和包被劑2-8°C，添加劑-20°C

DEF-CS系統(tǒng)是一個(gè)強(qiáng)大的培養(yǎng)系統(tǒng)，用于在無飼養(yǎng)層和確定環(huán)境下高效擴(kuò)增人誘導(dǎo)多能干細(xì)胞（iPS）。該系統(tǒng)能夠?qū)崿F(xiàn)穩(wěn)定的生長(zhǎng)速率，適合傳統(tǒng)iPS細(xì)胞培養(yǎng)，細(xì)胞批量生產(chǎn)和單細(xì)胞培養(yǎng)。用此培養(yǎng)系統(tǒng)生長(zhǎng)的細(xì)胞保持未分化狀態(tài)，不會(huì)有可檢測(cè)的背景分化，無需細(xì)胞選擇。酶法傳代的單細(xì)胞可用于單細(xì)胞相關(guān)應(yīng)用，包括高通量篩選，轉(zhuǎn)染和支架接種（scaffold seeding）。

☆ 成分確定、無血清、無飼養(yǎng)層培養(yǎng)

☆ All-In-One型：培養(yǎng)液+添加劑+包被劑

☆ 細(xì)胞單層生長(zhǎng)，可進(jìn)行單細(xì)胞傳代

☆ 維持未分化狀態(tài)，無需篩選分化細(xì)胞

☆ 單個(gè)干細(xì)胞基因操作實(shí)驗(yàn)的理想選擇

產(chǎn)品應(yīng)用

·放大和大規(guī)模生產(chǎn)人類iPS誘導(dǎo)多能干細(xì)胞

·人類iPS誘導(dǎo)多能干細(xì)胞的單細(xì)胞培養(yǎng)

·轉(zhuǎn)染和重編程

·高通量篩選

·組織工程（支架接種）

DEF-CS是單個(gè)誘導(dǎo)多能干細(xì)胞基因操作的理想選擇

Human iPS和Human ES增殖用培養(yǎng)基(DEF-CS Culture System, all-in-one format)

作為一款創(chuàng)新型的產(chǎn)品，Cellartis DEF-CS培養(yǎng)系統(tǒng)使得單細(xì)胞干細(xì)胞操作成為常規(guī)的操作。該產(chǎn)品是專門針對(duì)人類誘導(dǎo)多能干細(xì)胞（hiPS）和人類胚胎干細(xì)胞（hES）研發(fā)的高效率增殖用培養(yǎng)基產(chǎn)品體系。該產(chǎn)品系統(tǒng)為all-in-one型，包括了所有組分，客戶不需要另外求購組分。該產(chǎn)品是成分確定的培養(yǎng)基產(chǎn)品，而且不需要飼養(yǎng)層。DEF-CS既可以實(shí)現(xiàn)單細(xì)胞培養(yǎng)，也可以用于傳統(tǒng)的iPS培養(yǎng)模式以及大規(guī)模干細(xì)胞增殖。在使用DEF-CS培養(yǎng)基增殖干細(xì)胞時(shí)，幾乎沒有背景分化的問題，這使得細(xì)胞篩選不再必需。作為一款創(chuàng)新產(chǎn)品，利用DEF-CS培養(yǎng)干細(xì)胞時(shí)，可以使用酶消化法（enzymatic passaging）實(shí)現(xiàn)需要單細(xì)胞操作，這一特點(diǎn)十分有利于高通量細(xì)胞鑒別篩選（high-throughput screening）、轉(zhuǎn)染（transfection）、支架接種（scaffold seeding）等。

Cellartis DEF-CS 500 Culture System 組份

培養(yǎng)系統(tǒng)包括基礎(chǔ)培養(yǎng)基、包被劑和添加劑

Cellartis DEF-CS 500 Culture System (Cat. No. Y30010)

500 ml Cellartis DEF-CS 500 Basal Medium (Cat. No. Y30011; not sold separay)

4 ml Cellartis DEF-CS 500 COAT-1 (Cat. No. Y30012)

Cellartis DEF-CS 500 Additives (Cat. No. Y30016)：

o 2 x 750 µl DEF-CS GF-1

o 500 µl DEF-CS GF-2

o 200 µl DEF-CS GF-3

需要自行準(zhǔn)備試劑：PBS（含鈣鎂和不含鈣鎂），TrypLE選擇酶（無酚紅）

PBS Dulbecco's with Ca2+ & Mg2+ (D-PBS +/+)

PBS Dulbecco's w/o Ca2+ & Mg2+ (D-PBS –/–)

TrypLE Select Enzyme (1X), no phenol red

誘導(dǎo)多能干細(xì)胞培養(yǎng)性能

單細(xì)胞傳代

Human induced pluripotent stem (iPS) cells can be passaged as single cells in the Cellartis DEF-CS Culture System. A single GFP-actin iPS cell was isolated and placed in the well of a culture dish. Twenty-four hours after seeding, morphology was assessed by fluorescence microscopy at 20x (Panel A) and 40x (Panel B) magnification. Sixteen days later, the single GFP-actin iPS cell had proliferated into numerous cells as evidenced by microscopic observation at 4x (Panel C), 10x (Panel D), 20x (Panel E), and 40x (Panel F) magnification.

擴(kuò)增潛力

Expansion potential of a characterized working bank of human induced pluripotent stem (iPS) cells in the Cellartis DEF-CS Culture System. The Cellartis DEF-CS Culture System can produce 2 x 109 human iPS cells within 4 passages (18–20 days) from frozen cells (2.0–2.5 x 106 cells).

多能干性維持

Human pluripotent stem cells remain undifferentiated when cultured in the Cellartis DEF-CS Culture System. Human iPS cells cultured for 23 passages in the Cellartis DEF-CS Culture System were characterized by Oct-4 staining (A) and nuclear staining (B).

參考文獻(xiàn)：

1. Sivertsson, Louise, et al. "Hepatic differentiation and maturation of human embryonic stem cells cultured in a perfused     three-dimensional bioreactor." Stem cells and development 22.4 (2012): 581-594.

2. Hanson, Charles, et al. "Transplantation of human embryonic stem cells onto a partially wounded human cornea in     vitro." Acta ophthalmologica 91.2 (2013): 127-130.

3. Norrman, Karin, et al. "Distinct gene expression signatures in human embryonic stem cells differentiated towards definitive endoderm at single-cell level." Methods 59.1 (2013): 59-70.

4. Ulvestad, Maria, et al. "Drug metabolizing enzyme and transporter protein profiles of hepatocytes derived from human embryonic and induced pluripotent stem cells." Biochemical pharmacology 86.5 (2013): 691-702.

5. Ramirez JM, et al. Side scatter intensity is highly heterogeneous in undifferentiated pluripotent stem cells and predicts clonogenic self-renewal. Stem Cells Dev.2013 Jun 15;22(12):1851-1860.

6. Borestrom, Cecilia, et al. “Footprint-free human induced pluripotent stem cells from articular cartilage with redifferentiation capacity: A first step toward a clinical-grade cell source.” Stem Cells Trans. Med. (2014) 3, 433-447.

7. Kia, Richard, et al. "MicroRNA-122: a novel hepatocyte-enriched in vitro marker of drug-induced cellular toxicity." Toxicological Sciences (2014): kfu269.

8. Valton, Julien, et al. "Efficient strategies for TALEN-mediated genome editing in mammalian cell lines." Methods 69.2 (2014): 151-170.

9. Zandén, Carl, et al. "Stem cell responses to plasma surface modified electrospun polyurethane scaffolds." Nanomedicine: Nanotechnology, Biology and Medicine 10.5 (2014): 949-958.

10. Asplund, Annika, et al. “One Standardized Differentiation Procedure Robustly Generates Homogenous Hepatocyte Cultures Displaying? Metabolic Diversity from a Large Panel of Human Pluripotent Stem Cells” Stem Cell Rev and Rep (2015)

 ?華雅集團(tuán)旗下授權(quán)代理TTAKARA Cellartis干細(xì)胞產(chǎn)品，Cellartis的多能細(xì)胞培養(yǎng)系統(tǒng)包括iPS誘導(dǎo)多能干細(xì)胞株、iPS誘導(dǎo)多能干細(xì)胞和ES胚胎干細(xì)胞培養(yǎng)基，iPS基因編輯用單細(xì)胞克隆培養(yǎng)基和多能細(xì)胞檢測(cè)用單克隆抗體。

重慶市華雅干細(xì)胞技術(shù)有限公司以“專注干細(xì)胞研究，提升干細(xì)胞品質(zhì)”為發(fā)展理念，專業(yè)從事干細(xì)胞基礎(chǔ)研究、干細(xì)胞再生醫(yī)學(xué)臨床應(yīng)用研究及干細(xì)胞技術(shù)服務(wù)，自主研發(fā)產(chǎn)品熱賣中：人間充質(zhì)干細(xì)胞無血清培養(yǎng)基 

，  ：